Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 4
2005 1
2006 1
2007 1
2008 4
2009 1
2010 1
2011 3
2012 3
2013 4
2014 5
2015 4
2016 3
2017 5
2018 3
2019 4
2020 2
2021 6
2022 8
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Page 1
Intraoperative Ketorolac and Outcomes after Ovarian Cancer Surgery.
Luyckx M, Verougstraete C, Jouret M, Sawadogo K, Waterkeyn M, Grandjean F, Van Gossum JP, Dubois N, Malvaux V, Verreth L, Grandjean P, Jadoul P, Maillard C, Gerday A, Dieu A, Forget P, Baurain JF, Squifflet JL. Luyckx M, et al. Among authors: baurain jf. J Clin Med. 2024 Mar 7;13(6):1546. doi: 10.3390/jcm13061546. J Clin Med. 2024. PMID: 38541772 Free PMC article.
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial.
Pothuri B, Han S, Chase DM, Heitz F, Burger RA, Gaba L, Van Le L, Guerra E, Bender D, Korach J, Cloven N, Churruca C, Follana P, DiSilvestro P, Baurain JF, Jardon K, Pisano C, Peen U, Mäenpää J, Gupta D, Bacqué E, Li Y, Compton N, Antonova J, Monk BJ, González-Martín A. Pothuri B, et al. Among authors: baurain jf. Gynecol Oncol. 2024 Feb 6;184:168-177. doi: 10.1016/j.ygyno.2024.01.021. Online ahead of print. Gynecol Oncol. 2024. PMID: 38325276 Free article.
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, Sullivan RJ, Dummer R, Kirkwood JM, Orloff M, Sacco JJ, Ochsenreither S, Joshua AM, Gastaud L, Curti B, Piulats JM, Salama AKS, Shoushtari AN, Demidov L, Milhem M, Chmielowski B, Kim KB, Carvajal RD, Hamid O, Collins L, Ranade K, Holland C, Pfeiffer C, Nathan P. Hassel JC, et al. Among authors: baurain jf. N Engl J Med. 2023 Dec 14;389(24):2256-2266. doi: 10.1056/NEJMoa2304753. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870955 Clinical Trial.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Centralizing surgery for ovarian cancer in a 'non-centralizing' country (Belgium): the UNGO (UCLouvain Network of Gynaecological Oncology) experience.
Luyckx M, Jouret M, Sawadogo K, Waterkeyn M, Grandjean F, Van Gossum JP, Dubois N, Malvaux V, Verreth L, Grandjean P, Bruger AM, Jadoul P, Maillard C, Gerday A, Baurain JF, Squifflet JL. Luyckx M, et al. Among authors: baurain jf. Int J Gynecol Cancer. 2023 Oct 16;34(1):106-12. doi: 10.1136/ijgc-2023-004401. Online ahead of print. Int J Gynecol Cancer. 2023. PMID: 37844964 Free PMC article.
A randomized phase 2 study of sapanisertib in combination with paclitaxel versus paclitaxel alone in women with advanced, recurrent, or persistent endometrial cancer.
Han SN, Oza A, Colombo N, Oaknin A, Raspagliesi F, Wenham RM, Braicu EI, Jewell A, Makker V, Krell J, Alía EMG, Baurain JF, Su Z, Neuwirth R, Vincent S, Sedarati F, Faller DV, Scambia G. Han SN, et al. Among authors: baurain jf. Gynecol Oncol. 2023 Nov;178:110-118. doi: 10.1016/j.ygyno.2023.09.013. Epub 2023 Oct 14. Gynecol Oncol. 2023. PMID: 37839313 Free article. Clinical Trial.
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
Vergote I, Van Nieuwenhuysen E, O'Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, Collins DC, Banerjee S, Mathews CA, Gennigens C, Cibula D, Tewari KS, Madsen K, Köse F, Jackson AL, Boere IA, Scambia G, Randall LM, Sadozye A, Baurain JF, Gort E, Zikán M, Denys HG, Ottevanger N, Forget F, Mondrup Andreassen C, Eaton L, Chisamore MJ, Viana Nicacio L, Soumaoro I, Monk BJ. Vergote I, et al. Among authors: baurain jf. J Clin Oncol. 2023 Dec 20;41(36):5536-5549. doi: 10.1200/JCO.23.00720. Epub 2023 Aug 31. J Clin Oncol. 2023. PMID: 37651655 Free PMC article. Clinical Trial.
Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Mirza MR, González-Martín A, Graybill WS, O'Malley DM, Gaba L, Stephanie Yap OW, Guerra EM, Rose PG, Baurain JF, Ghamande SA, Denys H, Prendergast E, Pisano C, Follana P, Baumann K, Calvert PM, Korach J, Li Y, Malinowska IA, Gupta D, Monk BJ. Mirza MR, et al. Among authors: baurain jf. Cancer. 2023 Jun 15;129(12):1846-1855. doi: 10.1002/cncr.34706. Epub 2023 Apr 14. Cancer. 2023. PMID: 37060236 Clinical Trial.
72 results